Neurocrine to Acquire Soleno for $2.9 Billion, Bolstering Rare Disease Portfolio
Event summary
- Neurocrine Biosciences is acquiring Soleno Therapeutics for $53.00 per share, a total equity value of $2.9 billion.
- The acquisition includes VYKAT XR, an FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), launched in 2Q 2025 and generating $190 million in 2025 revenue.
- Neurocrine will add VYKAT XR to its portfolio alongside INGREZZA® ($2.51 billion revenue in 2025) and CRENESSITY® ($301 million revenue in 2025).
- The transaction is expected to close within 90 days, subject to customary conditions.
The big picture
Neurocrine’s acquisition of Soleno represents a strategic bet on the growing market for rare disease therapies, particularly those addressing unmet needs like hyperphagia in Prader-Willi syndrome. This $2.9 billion deal underscores the increasing value placed on first-in-class treatments and the willingness of large biopharma companies to pay a premium for assets with durable intellectual property and established commercial traction. The acquisition also signals a continued consolidation trend within the specialty pharmaceutical sector, as companies seek to bolster their portfolios and achieve scale.
What we're watching
- Commercial Execution
- The success of the acquisition hinges on Neurocrine’s ability to effectively integrate Soleno’s commercial operations and expand VYKAT XR’s reach beyond its current adoption rate.
- Patent Protection
- While VYKAT XR’s patent estate extends into the mid-2040s, potential generic competition or biosimilar development remains a long-term risk that could erode market share.
- Regulatory Scrutiny
- Given the acquisition’s size and Neurocrine’s increased market position, regulatory bodies may scrutinize the deal for potential antitrust concerns, potentially delaying or complicating the closing process.
Related topics